Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells

Journal of Molecular Biology

Volumn 399, Issue 4, 2010, Pages 596-603

  Li, Yili ^a,b   Depontieu, Florence R ^c   Sidney, John ^d   Salay, Theresa M ^c   Engelhard, Victor H ^e   Hunt, Donald F ^f   Sette, Alessandro ^d   Topalian, Suzanne L ^c   Mariuzza, Roy A ^a,b  

^a UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

^b University of Maryland   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Crystal structure; Melanoma; MHC class II; Phosphopeptide; T cell receptor

Indexed keywords

HLA DR1 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; MELANOMA ANTIGEN; PEPTIDE; PHOSPHOPEPTIDE; SERINE; T LYMPHOCYTE RECEPTOR;

AMINO TERMINAL SEQUENCE; ANTIGENICITY; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CRYSTAL STRUCTURE; HOST; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MELANOMA; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE;

EID: 77954762820     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2010.04.037     Document Type: Article

References (33)

1. Engelhard V.H., Altrich-Vanlith M., Ostankovitch M., Zarling A.L. Post-translational modifications of naturally processed MHC-binding epitopes. Curr. Opin. Immunol. 2006, 18:92-97.
2. Zarling A.L., Ficarro S.B., White F.M., Shabanowitz J., Hunt D.H., Engelhard V.H. Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J. Exp. Med. 2000, 192:1755-1762.
3. Zarling A.L., Polefrone J.M., Evans A.M., Mikesh L.M., Shabanowitz J., Lewis S.T., et al. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc. Natl Acad. Sci. USA 2006, 103:14889-14894.
4. Depontieu F., Qian J., Zarling A.L., McMiller T.L., Salay T.M., Norris A., et al. Identification of tumor-associated MHC class II-restricted phosphopeptides as targets for immunotherapy. Proc. Natl Acad. Sci. USA 2009, 106:12073-12078.
5. Blume-Jensen P., Hunter T. Oncogenic kinase signaling. Nature 2001, 411:355-365.
6. Ibrahim N., Haluska F.G. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu. Rev. Pathol. 2009, 4:551-579.
7. Williamson N.A., Rossjohn J., Purcell A.E. Tumors reveal their secrets to cytotoxic T cells. Proc. Natl Acad. Sci. USA 2006, 103:14649-14650.
8. + T cell responses in antitumor immunity. Curr. Opin. Immunol. 1998, 10:588-594.
9. Gerloni M., Zanetti M. CD4 T cells in tumor immunity. Springer Semin. Immunopathol. 2005, 27:37-48.
10. Meyer V.S., Drews O., Gunder M., Hennenlotter J., Rammensee H.G., Stevanovic S. Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I phospholigands. J. Proteome Res. 2009, 8:3666-3674.
11. Kawakami Y., Eliyahu S., Sakaguchi K., Robbins P.F., Rivoltini L., Yannelli J.R., et al. Identification of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 1994, 180:347-352.
12. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004, 10:909-915.
13. Mohammed F., Cobbold M., Zarling A.L., Salim M., Barrett-Wilt G.A., Shabanowitz J., et al. Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. Nat. Immunol. 2008, 9:1236-1243.
14. Petersen J., Wurzbacher S.J., Williamson N.A., Ramarathinam S.H., Reid H.H., Nair A.K.N., et al. Phosphorylated self-peptides alter human leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopes. Proc. Natl Acad. Sci. USA 2009, 106:2776-2781.
15. Frayser M., Sato A.K., Xu L., Stern L.J. Empty and peptide-loaded class II major histocompatibility complex proteins produced by expression in Escherichia coli and folding in vitro. Protein Expr. Purif. 1999, 15:105-114.
16. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276:307-326.
17. Storoni L.C., McCoy A.J., Read R.J. Likelihood-enhanced fast rotation functions. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60:432-438.
18. Zavala-Ruiz Z., Sturg I., Anderson M.W., Gorski J., Stern L.J. A polymorphic pocket in the P10 position contributes to peptide binding specificity in class II MHC proteins. Chem. Biol. 2004, 11:1395-1402.
19. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., et al. Crystallography & NMR systems: a new software suite for macromolecular structure determination. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1998, 54:905-921.
20. McRee D.E. XtalView/Xfit-a versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 1999, 125:156-165.
21. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26:283-291.
22. Southwood S., Sidney J., Kondo A., del Guernico M.F., Appella E., Hoffman S., et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 1998, 160:3363-3373.
23. Stern L.J., Brown J.H., Jardetzky T.S., Gorga J.C., Urban R.G., Strominger J.L., et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994, 368:215-221.
24. Ghosh P., Amaya M., Mellins E., Wiley D.C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995, 378:457-462.
25. Dessen A., Lawrence C.M., Cupo S., Zaller D.M., Wiley D.C. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB*0401) complexed with a peptide from human collagen II. Immunity 1997, 7:473-481.
26. Smith K.J., Pyrdol J., Gauthier L., Wiley D.C., Wucherpfennig K.W. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J. Exp. Med. 1998, 188:1511-1520.
27. + tumor-infiltrating lymphocyte line. J. Mol. Biol. 2002, 319:449-461.
28. Sidney J., Southwood S., Oseroff C., del Guercio M.F., Sette A., Grey H.M. The measurement of MHC/peptide interactions by gel infiltration. Curr. Protocols Immunol. 1998, 18:3.1-3.19.
29. Wucherpfennig K.W., Call M.J., Deng L., Mariuzza R.A. Structural alterations in peptide-MHC recognition by self-reactive T cell receptors. Curr. Opin. Immunol. 2009, 21:590-595.
30. Hahn M., Nicholson M.J., Pyrdol J., Wucherpfennig K.W. Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Nat. Immunol. 2005, 6:490-496.
31. Li Y., Huang Y., Lue J., Quandt J.A., Martin R., Mariuzza R.A. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J. 2005, 24:2968-2979.
32. Deng L., Langley R.J., Brown P.H., Xu G., Teng L., Wang Q., et al. Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor. Nat. Immunol. 2007, 8:398-408.
33. Hoashi T., Watabe H., Muller J., Yamaguchi Y., Vieira W.D., Hearing V.J. MART-1 is required for the function of the melanosomal matrix protein PMEL17/GP100 and the maturation of melanomasomes. J. Biol. Chem. 2005, 280:14006-14016.